There's an interesting tradeoff there. Getting through clinical trials to prove it works is expensive, though that's realistically more an annoyance to the comp

There's an interesting tradeoff there. Getting through clinical trials to prove it works is expensive, though that's realistically more an annoyance to the company than a problem for the public. But once you have gone through all of that, you're probably looking at the product now being sold for a higher price (increased barriers to entry means more competition), and possibly only by prescription. Which might severely reduce availability to less-wealthy smokers. Which, I think at this point, is most smokers. On the other hand, that would also severely reduce availability to kids who aren't already addicted to some other tobacco product. So there's that. Long story short, I can imagine a lot of valid arguments pointing in every which way here.